endoluminal solutions, Inc. has decided to relocate to a new office in early 2027 as part of our business expansion and efforts to strengthen our development and organizational capabilities.
The new office will be located near our current office and will include an experimental workspace to further advance our development activities, as well as office space for sales, administrative, and other functions.
The new environment will also support future team expansion as we work toward obtaining a medical device marketing authorization license and establishing a QMS (Quality Management System) in preparation for the practical application of our medical devices.
We will continue to strengthen our R&D and business foundation, accelerate the practical application and real-world implementation of innovative medical devices and systems, and contribute to addressing the challenges of gastric cancer screening.
